ERBB2 and neoplasm: Furthermore, the variability in HER2 expression, alongside the possibility of intratumoral heterogeneity—indicated by differing HER2 scores within the same tumor—underscores the need for more precise biomarker assessment methods (Zhu et al., 2024).